Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028
GPCR is trading near its 52-week low of $18.7 (14% above the low).
Summary
Structure Therapeutics reported a Q3 2026 net loss of $144.8M as Phase 3 spending ramped, backed by $1.2B in cash it says funds operations through 2028. Phase 3 aleniglipron topline is not due until 2H 2028, with three supplementary datasets expected in Q4 2026.
Key Events · Earnings and Guidance · GPCR
-
Q3 Net Loss Widens to $144.8M
Net loss was $144.8M versus $65.7M in Q3 2025, including $12.7M of non-cash share-based compensation.
-
R&D Spend Nearly Doubles
R&D rose to $134.6M from $59.0M a year earlier on clinical trial, preclinical and employee costs; G&A rose to $21.8M from $14.8M.
-
$1.2B Cash Funds Operations Through 2028
Cash, cash equivalents and short-term investments totaled $1.2B at September 30, 2026, down from $1.3B at June 30, 2026, funding milestones through end-2028 excluding pre-commercialization costs.
-
Phase 3 Topline Slated for 2H 2028
ACCOMPLISH-1 (up to 3,600 patients) and ACCOMPLISH-2 (up to 1,100 patients with T2DM) are enrolling; topline data expected in the second half of 2028.
Analysis · GPCR · Life Sciences
Spending is ramping hard as the Phase 3 ACCOMPLISH program for aleniglipron gets underway, and the quarterly numbers reflect it: R&D jumped to $134.6M from $59.0M a year ago, pushing the net loss to $144.8M from $65.7M. The offset is a $1.2B cash pile that management says funds operations and key clinical milestones through the end of 2028, so there is no near-term financing need. For valuation, the pipeline update is the part that matters: Phase 3 topline is not expected until 2H 2028, but three supplementary aleniglipron datasets (body composition, T2DM, SWITCH) are due in Q4 2026 and ACCG-2671 MAD data in 1H 2027 — those readouts are the nearer-term drivers.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GPCR was trading at $21.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.70 to $94.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.